The price-to-earnings ratio for Bellevue Life Sciences Acquisition Corp (NASDAQ: BLAC) is above average at 275.77x, Company’s 36-month beta value is -0.02.
The public float for BLAC is 2.81M, and currently, short sellers hold a 0.08% ratio of that floaft. The average trading volume of BLAC on April 26, 2024 was 40.83K shares.
BLAC) stock’s latest price update
Bellevue Life Sciences Acquisition Corp (NASDAQ: BLAC)’s stock price has increased by 0.14 compared to its previous closing price of 10.69.
BLAC’s Market Performance
Bellevue Life Sciences Acquisition Corp (BLAC) has seen a 0.00% fall in stock performance for the week, with a 0.38% gain in the past month and a 2.29% surge in the past quarter. The volatility ratio for the week is 0.03%, and the volatility levels for the past 30 days are at 0.09% for BLAC. The simple moving average for the last 20 days is 0.11% for BLAC stock, with a simple moving average of 3.04% for the last 200 days.
BLAC Trading at 0.79% from the 50-Day Moving Average
After a stumble in the market that brought BLAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.12% of loss for the given period.
Volatility was left at 0.09%, however, over the last 30 days, the volatility rate increased by 0.03%, as shares surge +0.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.29% upper at present.
During the last 5 trading sessions, BLAC remain unchanged, in comparison to the 20-day moving average, which settled at $10.69. In addition, Bellevue Life Sciences Acquisition Corp saw 1.90% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for BLAC
The total capital return value is set at -0.05. Equity return is now at value 2.49, with 2.13 for asset returns.
Currently, EBITDA for the company is -1.83 million with net debt to EBITDA at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.01.
Conclusion
In a nutshell, Bellevue Life Sciences Acquisition Corp (BLAC) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
